AIM: We investigated the nature and frequency of adverse events following immunization (AEFI) associated with oral polio vaccines (OPV) in the general population in Kinshasa, Democratic Republic of Congo (DR Congo). METHODS: The DR Congo National Pharmacovigilance Centre organized active AEFI surveillance during mass immunization campaigns for the general population from March to June 2011. A patient individual case safety report was used as a questionnaire and addressed to pupils and students from high schools and universities who had any adverse events after OPV administration. We used the preferred term from the WHO Adverse Reaction Terminology for AEFI designation. Here is presented the results of the second step of the mass immunization campaign. RESULTS: A total of 767 patients reported AEFI during the second step. Sex distribution shows that 512 (66·8%) students were females, while 255 (33·2%) were males, giving a female/male ratio 2∶1. The average age was 16·8±5·19 years (ranged: 6-35·5 years). Each person reported a mean of 1·33±0·6 AEFI. The average AEFI onset duration was 1·74±1·16 days post-vaccination, ranging from 1 to 9 days. Headache (22·4%), abdominal pain (17·2%), fever (11·7%), diarrhea (9·9%), and asthenia (7·5%) were the common symptoms. Paralysis and asthma-like reactions were rare and serious adverse events in this study. The most affected systems were gastro-intestinal (33·5%) and nervous system (29·3%). Rechallenge was positive for 173 persons (22·6%). CONCLUSION: OPV-related AEFIs are not uncommon, although it is under-reported. Active AEFI surveillance during mass immunization campaigns is very important and may help to detect rare and serious adverse events. Further investigation will be important to identify risk of AEFI with OPV in adults and is warranted to elucidate the cause of this association in the Congolese environment.
AIM: We investigated the nature and frequency of adverse events following immunization (AEFI) associated with oral polio vaccines (OPV) in the general population in Kinshasa, Democratic Republic of Congo (DR Congo). METHODS: The DR Congo National Pharmacovigilance Centre organized active AEFI surveillance during mass immunization campaigns for the general population from March to June 2011. A patient individual case safety report was used as a questionnaire and addressed to pupils and students from high schools and universities who had any adverse events after OPV administration. We used the preferred term from the WHO Adverse Reaction Terminology for AEFI designation. Here is presented the results of the second step of the mass immunization campaign. RESULTS: A total of 767 patients reported AEFI during the second step. Sex distribution shows that 512 (66·8%) students were females, while 255 (33·2%) were males, giving a female/male ratio 2∶1. The average age was 16·8±5·19 years (ranged: 6-35·5 years). Each person reported a mean of 1·33±0·6 AEFI. The average AEFI onset duration was 1·74±1·16 days post-vaccination, ranging from 1 to 9 days. Headache (22·4%), abdominal pain (17·2%), fever (11·7%), diarrhea (9·9%), and asthenia (7·5%) were the common symptoms. Paralysis and asthma-like reactions were rare and serious adverse events in this study. The most affected systems were gastro-intestinal (33·5%) and nervous system (29·3%). Rechallenge was positive for 173 persons (22·6%). CONCLUSION: OPV-related AEFIs are not uncommon, although it is under-reported. Active AEFI surveillance during mass immunization campaigns is very important and may help to detect rare and serious adverse events. Further investigation will be important to identify risk of AEFI with OPV in adults and is warranted to elucidate the cause of this association in the Congolese environment.
Entities:
Keywords:
Adverse events following immunization,; Democratic Republic of Congo; Kinshasa,; Oral poliovirus,; Students,
Authors: Deepika Mahajan; Ilnaz Roomiani; Michael S Gold; Glenda L Lawrence; Peter B McIntyre; Rob I Menzies Journal: Commun Dis Intell Q Rep Date: 2010-09
Authors: Claude-Roger Ouandaogo; Téné M Yaméogo; Fabien V K Diomandé; Charles Sawadogo; Bassirou Ouédraogo; Rasmata Ouédraogo-Traoré; Lorenzo Pezzoli; Mamoudou H Djingarey; Nehémie Mbakuliyemo; Patrick L F Zuber Journal: Vaccine Date: 2012-01-09 Impact factor: 3.641
Authors: Daniel N A Ankrah; Aukje K Mantel-Teeuwisse; Marie L De Bruin; Philip K Amoo; Charles N Ofei-Palm; Irene Agyepong; Hubert G M Leufkens Journal: Drug Saf Date: 2013-04 Impact factor: 5.606
Authors: Arnaud Le Menach; Augusto E Llosa; Isabelle Mouniaman-Nara; Felix Kouassi; Joseph Ngala; Naomi Boxall; Klaudia Porten; Rebecca F Grais Journal: Emerg Infect Dis Date: 2011-08 Impact factor: 6.883